People who contracted COVID-19 during one of the previous waves of the pandemic appeared to have a lower risk of developing the delta variant than those who received up to two doses of the Pfizer vaccine, according to a Bloomberg report, citing data from Israel. This, however, contradicts previous research findings.
- Israeli scientists share their data from continuously monitoring the COVID-19 pandemic
- This time, they have good news for people who have already contracted coronavirus infection
- This analysis showed that innate immunity provides stronger and longer protection against infection, disease, and hospitalization for the delta variant, the researchers said.
- However, this contradicts previous reports by other scientists
- More such information can be found on the home page of Onet.pl
In order to quell the COVID-19 pandemic, the world needs to develop what is called herd immunity. Antibodies are obtained by people who have had the infection and who have been vaccinated. According to the latest reports from Israeli doctors, the former are better protected from infection with the new delta type.
Bloomberg reports on the results of the observations. They compared people who had previously had COVID-19 with those who took two doses of Pfizer.
People who received two doses of the vaccine were about six times more likely to develop a delta infection and seven times more likely to develop symptoms of the disease than those who recovered.
The researchers also confirmed a decrease in immunity over time. The data has not been verified by other researchers.
The article by scholars from Israel contradicts previous research. According to PAP, the delta variant is resistant to antibodies produced after COVID-19 disease, according to a study by scientists from the Pasteur Institute in Paris, published in Nature in July. Moreover, a single dose of the vaccine also does not protect against this type of coronavirus.
earlier Swedish scientists, thanks to long-term research, have discovered that unimmunized convalescents after one year of infection with COVID-19 are still immune to the coronavirus.. Their antibodies are also resistant to the new Alpha and Delta variants. However, these results were not compared with those of the vaccinated.
The fact that convalescents are better protected does not mean that vaccination is not discouraged. Its efficacy is still high. Research conducted by scientists has shown that Pfizer and AstraZeneki vaccines are almost equally effective against the currently dominant delta variant of the coronavirus.versus the previously dominant alpha variant.
In an article published in the New England Journal of Medicine, researchers from Public Health England (PHE) acknowledge this A single dose of these vaccines does not provide adequate protection.
The effectiveness of two doses of the Pfizer-BioNTech vaccine in preventing symptoms of disease caused by the delta variant was estimated to be 88%. compared to 93.7%. against the alpha variable.
However, the efficacy against the delta variant of two doses of Oxford-AstraZeneca vaccine is expected to be 67 percent. Previously, it had a slightly lower rating, at 60 percent. The effectiveness of this vaccine against the alpha variant is expected to be 74.5 percent.
“Infuriatingly humble musicaholic. Problem solver. Reader. Hardcore writer. Alcohol evangelist.”